Expert Insights

In a debate at the 2022 Great Debates and Updates in Gastrointestinal Malignancies meeting, Daniel Brown, MD, FSIR, Vanderbilt University Medical Center, argued in favor of liver-directed therapy for patients with cholangiocarcinoma.

J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, discusses short-course vs long-course radiation therapy in rectal cancer, presented at the 2022 GDI GI Meeting.

Namrata Vijayvergia, MD, FACP, Fox Chase Cancer Center, discusses whether or not the role for HIPEC is necessary for cytoreductive surgery, a debate presented at the 2022 Great Debates and Updates in Gastrointestinal Malignancies.

Namrata Vijayvergia, MD, Fox Chase Cancer Center, discusses standard observation in systematic therapy following metastatic resection, a debate presented at the 2022 GDU GI Annual Meeting.

Carla Casulo, MD, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed FL.

Craig A Portell, MD, talks about a phase 2 study of venetoclax in combination with obinutuzumab and bendamustine for patients with high tumor burden FL as frontline therapy.

Connie Batlevi, MD, PhD, shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class oral selective EZH2 inhibitor, for patients with FL.

Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.

In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.